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In this issue of the European Journal of Nuclear Medicine
and Molecular Imaging, the article by Antunes et al.,
entitled “Are radiogallium-labelled DOTA-conjugated so-
matostatin analogues superior to those labelled with other
radiometals?”, provides another example of the high
potential of the
68Ge/
68Ga generator for PET applications
in nuclear medicine. The use of
68Ge/
68Ga generators in
nuclear medicine is very attractive for several reasons:
1. The 270-day half-life of the parent
68Ge allows use of
the generator for a long period, potentially up to 1 year
or even longer.
2. The 68-min half-life of
68Ga matches the pharmacoki-
netics of many peptides and other small molecules
owing to rapid diffusion, localisation at the target and
fast blood clearance.
3. The PET radionuclide
68Ga is continuously available at
a reasonable cost from a
68Ge/
68Ga generator, including
for centres without a cyclotron.
4. Besides the DOTA analogues of somatostatin [1–5],
DOTA-derivatised analogues of several other interest-
ing peptides have been developed, such as bombesin
[6–10], substance P [11, 12], neurotensin [13] and
CCK [14–16]. DOTA is an excellent ligand for binding
of gallium; as a consequence, DOTA-peptides can be
rapidly and efficiently labelled with
68Ga at high
specific activities [10, 17, 18], which implies that the
mass of peptide to be administered can be very low [6,
19, 20]. This is of particular interest in the case of
peptides with potential pharmacological side-effects,
including substance P, bombesin and CCK.
In addition, labelling with
68Ga is not restricted to
DOTA-derivatised compounds. As long ago as the 1970s
and 1980s, several
68Ga-labelled tracers were reported, e.g.
for haematological applications and for investigations of
myocardial, liver and kidney function [21–29], but the lack
of a reliable source of the radionuclide prohibited their
further development. It can be expected that the commercial
availability of
68Ge/
68Ga generators will stimulate radio-
chemists and radiopharmacists to develop new
68Ga-based
radiopharmaceuticals for PET application; hence the num-
ber of potential
68Ga tracers for clinical applications is very
likely to expand in the near future.
On the other hand, despite these encouraging prospects
and the favourable results of recent clinical studies using
68Ga-labelled peptides, there is still quite a long way to go
before
68Ga-labelled compounds become standard radio-
pharmaceuticals for widespread use in daily nuclear
medicine routine. The reason for this has to be sought
mainly in the requirements imposed by pharmaceutical
legislation. Thus far, no company has a marketing autho-
risation for a
68Ge/
68Ga generator. Such a marketing
authorisation is a strict requirement for a radionuclide
generator from which is produced a daughter radionuclide
that is to be obtained by elution and used in a radiophar-
maceutical, as clearly stated by Directive 2001/83/EC of
the European Parliament and of the European Council, art.
Eur J Nucl Med Mol Imaging (2007) 34:978–981
DOI 10.1007/s00259-007-0387-4
This editorial commentary refers to the article http://dx.doi.org/
10.1007/s00259-006-0317-x.
W. A. P. Breeman (*)
Erasmus MC Rotterdam,
Dr Molewaterplein 40,
3015 GD Rotterdam, The Netherlands
e-mail: w.a.p.breeman@erasmusmc.nl
A. M. Verbruggen
Laboratory of Radiopharmacy,
Katholieke Universiteit Leuven,
Leuven, Belgium6.2 (November 6, 2001) on the community code relating to
medicinal products for human use. Among many other
requirements, such as those relating to establishment of
chemical, radiochemical and radionuclidic purity of the
eluate, the granting of a marketing authorisation for a
68Ge/
68Ga generator is dependent on the condition that it is
manufactured under conditions of good manufacturing
practice (GMP). Indeed, the eluate of such a generator is
to be considered as an active substance used as a starting
material for a medicinal product for human use. Article 46
(f) of European Directive 2001/83/EC and Article 50 (f) of
Directive 2001/82/EC, as amended by Directives 2004/27/
EC and 2004/28/EC respectively, place new obligations on
manufacturing authorisation holders to use only active
substances that have been manufactured in accordance with
GMP for starting materials [30]. To the best of our
knowledge, no such GMP-produced generator is yet
available on the European market, although some compa-
nies seem to be exploring the idea. In this respect, a clear
expression of interest from the nuclear medicine communi-
ty may help to speed up decisions in companies’ headquar-
ters and the necessary extensive preparatory work.
Apart from the need for an authorised
68Ga generator of
“medicinal quality”, the use of
68Ga-labelled agents as
radiopharmaceuticals is dependent on many conditions,
rules and laws. The simplest and most straightforward way
to permit the use of such tracers in an authorised way
would be for a manufacturer of medicinal products to
obtain a marketing authorisation for one or more labelling
kits for the preparation of
68Ga-labelled radiopharmaceu-
ticals and to make these kits available on the market. As is
the case for the development of any new diagnostic or
therapeutic drug, this work would take many years and cost
millions of euros, requiring the elaboration of a complete
dossier, including optimisation of manufacturing and
analytical methods, establishment of pharmacological and
radiation safety and extensive clinical studies to demon-
strate the real clinical value and profit. In the most
optimistic view, it would take at least 5 years for an
approved
68Ga radiopharmaceutical or labelling kit to
become commercially available.
As an alternative, and in view of the several promising
literature reports on the clinical benefit of
68Ga-labelled
peptides for specific and sensitive diagnosis of some
pathologies (see above), one could argue that a medical
doctor might rely on his or her therapeutic (and diagnostic)
freedom of choice, one of the main elements of the medical
profession, and thus might exercise personal responsibility
to use any (radioactive) compound that he or she judges
useful for the welfare of the patient. This argument is valid
and in principle allows much earlier use of interesting new
medicinal products, especially in the case of tracers of
which only nanomolar amounts have to be administered
once or a few times, thus entailing minimal risks of toxicity
or side-effects. In this case, however, each
68Ga-labelled
preparation would have to be considered as a magistral or
officinal preparation, subject to the restrictions and require-
ments of such preparations. A magistral preparation/
product is defined as any medicinal product, prepared in a
pharmacy in accordance with a medical prescription for an
individual patient (commonly known as the magistral
formula). An officinal preparation/product is any medicinal
product which is prepared in a pharmacy in accordance
with the prescriptions of a pharmacopoeia and is intended
to be supplied directly to the patients served by the
pharmacy in question (commonly known as the officinal
formula) [31]. In view of the absence of pharmacopoeial
monographs on
68Ga-labelled compounds to date, the only
possibility of using such tracers at present seems to be in
the form of a magistral preparation under the responsibility
of the prescribing physician.
In view of the above-described legal definitions,
68Ga-
labelled tracers used as magistral (or, in the future,
officinal) preparations necessarily have to be made by or
under the responsibility of a (radio)pharmacist and only
may be used for the patient(s) served by the pharmacy in
question. In addition, only starting materials produced
under GMP conditions by approved manufacturers of
pharmaceutical ingredients may be used [30]. This requires
that the ligands for complexation of
68Ga, such as
DOTATOC, DOTANOC, DOTATATE and other gallium
binding agents, must have a certificate of GMP production.
Moreover, they must be certified to meet the (purity)
requirements described in a pharmacopoeial monograph, or
in the absence of such a monograph, a monograph of the
manufacturer approved by pharmaceutical authorities. Fi-
nally, the pharmacist in charge of such a preparation has
full responsibility for the quality of the final radiopharma-
ceutical and thus should be able to rely on well-defined
specifications as described in a pharmacopoeial or other-
wise approved monograph.
As already stated, there are not yet monographs in the
European Pharmacopoeia (Ph. Eur.) on the eluate of
68Ga
generators, on ligands for complexation of
68Ga or on final
68Ga-labelled radiopharmaceuticals. This means that every
manufacturer of
68Ga generators or
68Ga-binding ligands
which are intended to be used in the preparation of a
radiopharmaceutical and every (radio)pharmacist responsi-
ble for a final
68Ga-labelled radiopharmaceutical has to
develop and receive approval for his own monograph(s).
Apart from the low efficiency of such dispersed efforts,
there is the potential problem of non-uniform requirements
for these products throughout Europe.
In view of this situation, the initiative has already been
taken to ask the European Pharmacopoeia Commission to
allow Ph. Eur. expert group 14 (group on radioactive
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graphs on
68Ga solutions for labelling (the eluate of a
68Ga
generator), on DOTATOC as a first
68Ga-binding peptide
and on
68Ga-DOTATOC as a first
68Ga radiopharmaceuti-
cal. The existence of such monographs would significantly
facilitate the use of
68Ga radiopharmaceuticals as a
magistral or officinal preparation and also, over a longer
time scale, the approval and granting of marketing author-
isations for the starting materials and
68Ga radiopharma-
ceuticals. The development of these monographs could take
quite some time, depending on the consensus on and
complexity of the required analytical methods for estab-
lishment of chemical, radiochemical, radionuclidic and
microbiological purity. However, input from radiopharma-
cists and radiochemists already familiar with such prepara-
tions for clinical studies and willingness to share
information on analytical procedures and safety determi-
nations might significantly contribute to the efficiency of
the process and speed it up.
New specific radiopharmaceuticals are cornerstones for
the survival and strength of nuclear medicine, but their
development and the possibility of their early use are
compromised by a number of factors such as the complex-
ity of pharmaceutical legislation and regulations, the
lengthy process of obtaining a marketing authorisation
and in some cases a limited return on investment. In the
case of diagnostic radiopharmaceuticals, the principle of
magistral or officinal preparations may be a solution that
allows physicians and their patients more flexible and early
access to valuable new tracers, evidently only on the
condition of sufficient guarantees for the safety of the
patient and the efficacy of the clinical investigations. This
requires a common strategy, disciplined adherence to basic
pharmaceutical rules and a joint effort by all professionals
in the field, radiopharmacists, radiochemists and nuclear
medicine physicians, to prove and guarantee the safety,
efficacy and purity of such agents. Under such conditions,
the further introduction of new
68Ga-labelled and other
radiopharmaceuticals is a realistic expectation and may
constitute an important boost to our field.
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